Stock Report

Download full stock data and analysis for free Last Updated: 29-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Marksans Pharma Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: MARKSANS | BSE: 524404

₹329.70

up-down-arrow ₹3.55 (1.09%)

As on 28-Aug-2026IST

Market cap

info icon

₹14,932 Cr

Revenue (TTM)

info icon

₹3,172 Cr

P/E Ratio

info icon

28.9

P/B Ratio

info icon

4.7

Div. Yield

info icon

0.3 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -1.79 35.61 19.59 18.25 17.87
EBIT 9.96 144.31 46.61 25.00 14.58
Net Profit 6.10 169.50 47.58 23.36 15.54
EPS 6.10 169.50 47.58 21.16 13.21
Book Value -- -- 22.41 20.06 25.20
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 17.2716.3419.3417.0217.13
Net Margin info 14.0713.6615.9213.8514.23
Return on equity info 16.2417.2118.1015.3116.89
Return on Capital info 22.0022.54--21.1022.50
Return on Assets info 12.5712.8814.6811.8512.93
Debt to Equity (x) info ----0.000.010.01

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
--
21.10
22.50
22.40
22.89
Peer Median
0.43
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

18.10

Higher than Peers by 18.62

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
18.10
15.31
16.89
16.53
18.59
Peer Median
-0.52
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

14.68

Higher than Peers by 15.01

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
14.68
11.85
12.93
12.93
13.78
Peer Median
-0.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

19.34

Higher than Peers by 15.88

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
19.34
17.02
17.13
17.65
15.52
Peer Median
3.45
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

15.92

Higher than Peers by 17.14

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
15.92
13.85
14.23
14.13
13.88
Peer Median
-1.22
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
--
17.07
16.97
17.00
15.55
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

19.59

Lower than Peers by 2.24

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
19.59
12.51
20.46
17.56
24.23
Peer Median
21.83
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

46.61

Lower than Peers by 664.98

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
46.61
11.76
16.91
33.69
34.27
Peer Median
711.58
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

47.58

Higher than Peers by 429.63

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
47.58
9.79
21.51
18.68
42.02
Peer Median
-382.05
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

47.58

--

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
47.58
9.81
21.32
17.80
30.32
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
--
22.41
19.46
18.33
57.34
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
--
0.01
0.01
0.01
0.02
Peer Median
0.31
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
--
0.01
0.01
0.01
0.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

5.17

Higher than Peers by 4.10

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
5.17
5.17
4.62
4.78
4.91
Peer Median
1.07
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.32

Higher than Peers by 2.70

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
3.32
3.32
2.85
3.19
3.49
Peer Median
0.62
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

28.55

Higher than Peers by 28.19

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
28.55
24.24
44.22
38.80
37.99
Peer Median
0.36
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

20.32

Lower than Peers by 2.40

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
20.32
21.84
20.59
20.81
22.51
Peer Median
22.73
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.89

Higher than Peers by 0.61

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
0.89
0.86
0.93
0.94
1.06
Peer Median
0.29
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
--
71.16
65.99
69.35
72.63
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
--
109.20
97.24
87.89
81.36
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
--
91.82
91.59
87.70
85.31
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
--
88.55
71.65
69.54
68.67
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

28.90

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
28.90
17.04
26.48
21.89
11.99
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

4.70

Higher than Peers by 4.26

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
4.70
2.36
4.08
3.33
1.83
Peer Median
0.43
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

0.27

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
0.27
0.57
0.36
0.40
0.71
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

17.12

Lower than Peers by 60.41

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
17.12
9.02
15.68
12.23
6.32
Peer Median
77.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

14,932

Higher than Peers by 12,399

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Marksans Pharma
14,932
7,121
10,076
6,868
3,194
Peer Median
2,533
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...